News
MYO
1.760
-1.68%
-0.030
Myomo's Return On Capital Employed Insights
Myomo (AMEX:MYO) brought in sales totaling $3.87 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 2.99%, resulting in a loss of $2.81 million.
Benzinga · 06/16 14:02
Myomo To Present at the Sidoti Summer Small Cap Virtual Investor Conference
BOSTON, June 09, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that Paul ...
Business Wire · 06/09 20:05
11 Best Robotics Stocks Under $10
In this article, we discuss the 11 best robotics stocks under $10. If you want to skip our detailed analysis of the robotics industry, go directly to 5 Best Robotics Stocks Under $10. Many key industries around the globe are increasingly adopting the use o...
Insider Monkey · 05/25 14:34
Stocks That Hit 52-Week Lows On Monday
  On Monday, 149 companies reached new 52-week lows.
Benzinga · 05/23 16:12
Recap: Myomo Q1 Earnings
Myomo (AMEX:MYO) reported its Q1 earnings results on Wednesday, May 11, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Myomo beat estimated earnings by 22.64%, reporting an EPS of $-0.41 versus an estimate of $-0.53.
Benzinga · 05/11 22:33
Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
Myomo, Inc. (MYO) delivered earnings and revenue surprises of 24.07% and 35.72%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 22:05
Myomo Says $1.7M Of License Revenue Is Expected To Be Recorded In Q2, Assuming Receipt Of Final Payment Of License Fee From China JV
“As the growing pipeline of MyoPro candidates converts into orders, we continue to expect year-over-year product revenue growth in 2022. Assuming receipt of the final payment of the license fee from our joint
Benzinga · 05/11 20:33
Myomo Q1 EPS $(0.41) Beats $(0.53) Estimate, Sales $3.90M Beat $2.85M Estimate
Myomo (AMEX:MYO) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.53) by 22.64 percent. This is a 28.07 percent increase over losses of $(0.57) per share from the same
Benzinga · 05/11 20:32
Myomo GAAP EPS of -$0.41 beats by $0.12, revenue of $3.87M beats by $1.01M
Myomo press release (NYSE:MYO): Q1 GAAP EPS of -$0.41 beats by $0.12. Revenue of $3.87M (+65.4% Y/Y) beats by $1.01M.
Seekingalpha · 05/11 20:14
-- Earnings Flash (MYO) MYOMO Reports Q1 Revenue $3.9M, vs. Street Est of $2.86M
MT Newswires · 05/11 16:27
Myomo Q1 2022 Earnings Preview
Myomo (MYO) is scheduled to announce Q1 earnings results on Wednesday, May 11th, after market close. The consensus EPS Estimate is -$0.53 and the consensus Revenue Estimate is $2.86M (+22.2%
Seekingalpha · 05/10 21:35
Myomo Earnings Preview
Myomo (AMEX:MYO) is set to give its latest quarterly earnings report on Wednesday, 2022-05-11. Here's what investors need to know before the announcement. Analysts estimate that Myomo will report an earnings per share (EPS) of $-0.53.
Benzinga · 05/10 16:39
Myomo receives partial payment for technology license fee from China JV
Medical robotics firm Myomo (NYSE:MYO) said its Chinese joint venture firm Jiangxi Myomo Medical Assistive Appliance had paid a portion of the technology license fee. The company said it received $1M
Seekingalpha · 04/04 21:05
BRIEF-Myomo Reports Progress With China Joint Venture, Receives Partial Payment Of Technology License Fee
reuters.com · 04/04 20:17
Myomo Reports Received Partial Payment Of Technology License Fee Related To Its Chinese Joint Venture
Myomo, Inc. (NYSE:MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis,
Benzinga · 04/04 20:16
Myomo Reports Progress with China Joint Venture, Receives Partial Payment of Technology License Fee
BOSTON, April 04, 2022--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, provides an update on the...
Business Wire · 04/04 20:15
Mid-Afternoon Market Update: Crude Oil Down Over 2%; Fossil Group Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling 200 points on Thursday.
Benzinga · 03/10 19:35
Mid-Day Market Update: Nasdaq Drops 250 Points; CrowdStrike Shares Gain On Upbeat Earnings
U.S. stocks opened on a weak note this morning, with the Nasdaq falling 250 points on Thursday.
Benzinga · 03/10 17:52
45 Stocks Moving In Thursday's Mid-Day Session
Gainers CEA Industries Inc. (NASDAQ: CEAD) shares surged 33.4% to $2.7350 after the company reported it signed a $2.1 million contract.
Benzinga · 03/10 17:25
Kala, Natera top healthcare gainers; Sunshine Biopharma, Myomo lead losers' pack
Gainers: Kala Pharmaceuticals (NASDAQ:KALA) +20%. Natera (NASDAQ:NTRA) +17%. Chemomab Therapeutics (NASDAQ:CMMB) +13%. Selecta Biosciences (NASDAQ:SELB) +11%. Longeveron (NASDAQ:LGVN) +7%. Losers: Sunshine Biopharma (NASDAQ:SBFM) -32%. Myomo (NYSE:MYO) -28...
Seekingalpha · 03/10 15:07
More
Webull provides a variety of real-time MYO stock news. You can receive the latest news about Myomo through multiple platforms. This information may help you make smarter investment decisions.
About MYO
Myomo, Inc. is a wearable medical robotics company that offers functional improvement for those with neuromuscular disorders and upper limb paralysis. The Company develops and markets the MyoPro product line. Its MyoPro is a myoelectric-controlled upper limb brace (orthosis), which is a rigid brace used for the purpose of supporting a patient's weak or paralyzed arm to enable and help improve functional activities of daily living (ADLs) in the home and community. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury and other neurological disorders. It primarily provides devices directly to patients and bill their insurance companies. It also sells its products through various other sales channels, including orthotic and prosthetic (O&P) providers, the Veterans Administration (VA) and to its distributors in certain accounts and geographic markets.